CMB.AU Cambium Bio Limited
Market Closed 04-17 16:12:00 AEST
0.30
+0.00
0.00%
High
0.30
Low
0.30
Vol
0.00
Open
0.30
D1 Closing
0.30
Amplitude
0.00%
Mkt Cap
5.48M
Tradable Cap
1.29M
Total Shares
18.28M
T/O
0.00
T/O Rate
0.00%
Tradable Shares
4.29M
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
Loading ...
News
New Post(s)
Profile
Cambium Bio Says FDA Approves Potency Assay Strategy
Reuters · 03-18
Cambium Bio Says FDA Approves Potency Assay Strategy
Turkish bank BankPozitif partners with Taurus for crypto custody
Grafa · 03-05
Turkish bank BankPozitif partners with Taurus for crypto custody
BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
Reuters · 02-25
BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol
Small Caps · 02-25
Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol
Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular
The Market Herald · 02-25
Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular
Cambium Bio Ltd - FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol
THOMSON REUTERS · 02-24
Cambium Bio Ltd - FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol
Cambium Bio Ltd-Placement Shares Cleansing Notice
THOMSON REUTERS · 2024-12-12
Cambium Bio Ltd-Placement Shares Cleansing Notice
BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular
Reuters · 2024-12-09
BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular
Cambium Bio Ltd-FDA Grants Fast Track Designation
THOMSON REUTERS · 2024-12-08
Cambium Bio Ltd-FDA Grants Fast Track Designation
Cambium Bio Successfully Closes a$3.0M Financing Round
THOMSON REUTERS · 2024-12-05
Cambium Bio Successfully Closes a$3.0M Financing Round
Press Release: Cambium Bio Successfully Closes A$3.0M Financing Round
Dow Jones · 2024-12-05
Press Release: Cambium Bio Successfully Closes A$3.0M Financing Round
BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital Raising
Reuters · 2024-12-02
BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital Raising
Cambium Bio Ltd - Trading Halt Requested Due to Proposed Capital Raising Announcement
THOMSON REUTERS · 2024-12-02
Cambium Bio Ltd - Trading Halt Requested Due to Proposed Capital Raising Announcement
BRIEF-Cambium Bio Says CEO Karolis Rosickas Has Acquired Additional 38,717 Shares Of Co
Reuters · 2024-10-15
BRIEF-Cambium Bio Says CEO Karolis Rosickas Has Acquired Additional 38,717 Shares Of Co
Cambium Bio Ltd - CEO Karolis Rosickas Has Acquired Additional 38,717 Shares of Co
THOMSON REUTERS · 2024-10-15
Cambium Bio Ltd - CEO Karolis Rosickas Has Acquired Additional 38,717 Shares of Co
ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects
GlobeNewswire · 2024-10-11
ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects
Bybit Türkiye recognised by Turkish regulator with key approval
Grafa · 2024-09-23
Bybit Türkiye recognised by Turkish regulator with key approval
Load more
Introduction
Company Name.
Cambium Bio Limited
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App
{"stockData":{"symbol":"CMB.AU","market":"AU","secType":"STK","nameCN":"Cambium Bio Limited","latestPrice":0.3,"timestamp":1744870320000,"preClose":0.3,"halted":0,"volume":0,"delay":0,"nameEN":"Cambium Bio Limited","floatShares":4291164,"shares":18282666,"eps":-0.0015,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:12:00 AEST","open":0.3,"high":0.3,"low":0.3,"amount":0,"amplitude":0,"askPrice":0.3,"askSize":1727,"bidPrice":0.295,"bidSize":2104,"shortable":3,"etf":0,"ttmEps":-0.0015,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.3,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/CMB.AU","defaultTab":"news","newsList":[{"id":"2520763447","title":"Cambium Bio Says FDA Approves Potency Assay Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2520763447","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520763447?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 09:05","pubTimestamp":1742259956,"startTime":"0","endTime":"0","summary":"March 18 (Reuters) - Cambium Bio Ltd ::*FDA APPROVES CAMBIUM BIO'S POTENCY ASSAY STRATEGY FOR ELATE OCULAR PHASE 3 CLINICAL TRIALS*Further company coverage: CMB.AX* ((Reuters.Briefs@thomsonreuters.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nRSD806ZCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2517995308","title":"Turkish bank BankPozitif partners with Taurus for crypto custody","url":"https://stock-news.laohu8.com/highlight/detail?id=2517995308","media":"Grafa","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517995308?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 10:39","pubTimestamp":1741142397,"startTime":"0","endTime":"0","summary":"Turkish digital bank BankPozitif is set to introduce cryptocurrency custody services in partnership with Swiss crypto platform Taurus.The service, expected to launch by June, will cater to institutional clients and initially support Bitcoin , Ether , Tether , XRP , and Solana , according to a bank spokesperson.On March 4, BankPozitif announced its collaboration with Taurus, marking another step by Turkish banks into digital asset services.“Crypto is a very hype topic. We believe that other players will also be active in the Turkish market,” a BankPozitif spokesperson stated, citing Turkey’s young population and increasing financial literacy as key factors driving demand.The bank has secured a temporary crypto custody license from Turkey’s Capital Markets Board , BankPozitif chairman Erkan Kork confirmed.According to public CMB data, BankPozitif is among 88 firms that have declared their intent to operate under Temporary Article 11 of the Capital Markets Law No. 6362.Other Turkish banks","market":null,"thumbnail":"https://images.grafa.com/grafa/media-cryptocurrencies-turkish-bank-bankpozitif-partners-with-taurus-for-crypto-custody-389841-638767391979114812.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-cryptocurrencies-turkish-bank-bankpozitif-partners-with-taurus-for-crypto-custody-389841-638767391979114812.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/cryptocurrencies-turkish-bank-bankpozitif-partners-with-taurus-for-crypto-custody-389841?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TON.USD.HKCC","APT.USD.CC","BTC.USD.HKCC","APT.USD.HKCC","TON.USD.CC","USDT.USD.CC","SOL.USD.HKCC","BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514303111","title":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514303111","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514303111?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 13:09","pubTimestamp":1740460163,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial ProtocolFeb 25 (Reuters) - Cambium Bio Ltd CMB.AX:FDA APPROVES ELATE OCULAR PHASE 3 CLINICAL TRIAL PROTOCOLFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514039295","title":"Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514039295","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514039295?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 12:38","pubTimestamp":1740458334,"startTime":"0","endTime":"0","summary":"Cambium Bio has received approval from the US Food and Drug Administration for a protocol relating to Phase 3 clinical trials of its Elate Ocular treatment for moderate-to-severe dry eye disease.The approval represents a key milestone in advancing Elate Ocular towards market registration and follows the FDA granting the product fast-track designation in December.Fast-tracking helps expedite the review of drugs that treat serious conditions and address unmet medical needs.Chief executive officer Karolis Rosickas said the Phase 3 protocol was pivotal to the development of the Elate Ocular trials.“The trial design reflects extensive consultation with regulatory experts and key opinion leaders to ensure we meet FDA requirements for registration,” he said.The fast-track designation will enable Cambium to have more frequent interactions with the FDA throughout Elate Ocular’s development process and makes the product eligible for potential accelerated approvals and priority reviews.“With fa","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/cambium-bio-us-fda-approval-phase-3-elate-ocular-dry-eye-disease-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2514708970","title":"Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2514708970","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514708970?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 08:37","pubTimestamp":1740443820,"startTime":"0","endTime":"0","summary":"Cambium Bio has flagged approval from the U.S. FDA for phase three of a clinical trial using its Elate Ocular product to treat moderate to severe dry eye disease.The market clearly liked the news – Cambium jumped more than 40% in the second hour of trade; the latest winner in a small basket of biotech stocks progressing towards late-stage approvals and commercialisation.In Cambium’s own words, the Phase 3 trial represents a final step towards market registration for its Elate Ocular product, with the third trial typically being the final in the FDA’s approval ringer. The Phase 3 program is ultimately geared to acquire a Biologics Licence Application . Trial sites in both the U.S. and Australia – “and select other countries” – will constitute Phase 3; Cambium won FDA Fast Track designation for Elate last December.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cambium-jumps-43-as-fda-approves-phase-3-trial-for-elate-ocular-2025-02-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2514670775","title":"Cambium Bio Ltd - FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670775?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 07:15","pubTimestamp":1740438945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2490825133","title":"Cambium Bio Ltd-Placement Shares Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490825133?lang=en_us&edition=full_marsco","pubTime":"2024-12-12 12:30","pubTimestamp":1733977836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUEGJDCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2490926764","title":"BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2490926764","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490926764?lang=en_us&edition=full_marsco","pubTime":"2024-12-09 09:13","pubTimestamp":1733706808,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate OcularDec 9 (Reuters) - Cambium Bio Ltd CMB.AX:FDA GRANTS FAST TRACK DESIGNATIONUS FDA GRANTS FAST TRACK DESIGNATION TO CAMBIUM BIO'S ELATE OCULARFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUE28QH18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2490591766","title":"Cambium Bio Ltd-FDA Grants Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490591766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490591766?lang=en_us&edition=full_marsco","pubTime":"2024-12-09 07:56","pubTimestamp":1733702207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUE28QH18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2489105996","title":"Cambium Bio Successfully Closes a$3.0M Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2489105996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489105996?lang=en_us&edition=full_marsco","pubTime":"2024-12-05 11:58","pubTimestamp":1733371085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA1CZPCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2489105737","title":"Press Release: Cambium Bio Successfully Closes A$3.0M Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2489105737","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489105737?lang=en_us&edition=full_marsco","pubTime":"2024-12-05 11:58","pubTimestamp":1733371080,"startTime":"0","endTime":"0","summary":"SYDNEY, Dec. 05, 2024 -- Cambium Bio Limited , a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the successful completion of a A$3.0 million capital raising.-- Capital raising of A$3.0 million completed at A$0.4637 per share,representing a 25% discount to the 5-day Volume Weighted Average Price. -- Strong support from new strategic investor AventaCell Biomedical Corp and. -- Additional participation from Cambium Bio directors, CEO, and Australian. -- Proceeds to advance Phase 3 clinical development of Elate Ocular for. The proceeds will primarily support the advancement of Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease, which are planned to commence in calendar Q2 2025. The funds will also provide working capital for the Company's ongoing operations.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","R","BK4232","BK4022","BK7067"],"gpt_icon":0},{"id":"2488494026","title":"BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2488494026","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488494026?lang=en_us&edition=full_marsco","pubTime":"2024-12-02 14:04","pubTimestamp":1733119490,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital RaisingDec 2 (Reuters) - Cambium Bio Ltd CMB.AX:TRADING HALT REQUESTED DUE TO PROPOSED CAPITAL RAISING ANNOUNCEMENTFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N3030:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2488649111","title":"Cambium Bio Ltd - Trading Halt Requested Due to Proposed Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2488649111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488649111?lang=en_us&edition=full_marsco","pubTime":"2024-12-02 14:03","pubTimestamp":1733119413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N3030:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2475308551","title":"BRIEF-Cambium Bio Says CEO Karolis Rosickas Has Acquired Additional 38,717 Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2475308551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475308551?lang=en_us&edition=full_marsco","pubTime":"2024-10-15 14:09","pubTimestamp":1728972558,"startTime":"0","endTime":"0","summary":"Oct 15 (Reuters) - Cambium Bio Ltd : * CEO KAROLIS ROSICKAS HAS ACQUIRED ADDITIONAL 38,717 SHARES OF CO Further company coverage: ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2475738513","title":"Cambium Bio Ltd - CEO Karolis Rosickas Has Acquired Additional 38,717 Shares of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2475738513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475738513?lang=en_us&edition=full_marsco","pubTime":"2024-10-15 09:54","pubTimestamp":1728957285,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LQ0X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2474183062","title":"ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2474183062","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474183062?lang=en_us&edition=full_marsco","pubTime":"2024-10-11 19:00","pubTimestamp":1728644400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Oct. 11, 2024 -- ATHA Energy Corp. is pleased to announce, in furtherance to its news release from August 20th, 2024 , the Company and Terra Uranium Ltd. have executed a definitive option agreement for T92 to earn an option to acquire a 70% interest in ATHA’s Spire and Horizon properties and a definitive option agreement for ATHA to earn an option to acquire up to a 60% interest in T92’s Pasfield Lake property .In accordance with the terms of the Option Agreement ATHA shall grant T92 the sole and exclusive right and option to acquire up to a 70% interest in the Spire Horizon Projects in consideration for incurring a minimum of $4,750,000 exploration expenditures as set out below:. on or before September 21, 2025, T92 must incur additional statutory exploration expenditures of at least $1,000,000 ;In accordance with the terms of the Option Agreement, T92 shall grant to ATHA the four exclusive and separate rights and options to acquire undivided lega","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QvgTN87.iuCU61yGwX1Z7g--~B/aD0yNDI7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4ad732e90ee5abcdfbb0f65a1a334ef4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QvgTN87.iuCU61yGwX1Z7g--~B/aD0yNDI7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4ad732e90ee5abcdfbb0f65a1a334ef4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atha-energy-announces-option-agreements-110000205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["UEC","BK7083","BK4007","CMB.AU","BK7067","BK4156","ATHA","T92.AU","BK4197","SASKF","SR"],"gpt_icon":0},{"id":"2469170885","title":"Bybit Türkiye recognised by Turkish regulator with key approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2469170885","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469170885?lang=en_us&edition=full_marsco","pubTime":"2024-09-24 07:29","pubTimestamp":1727134141,"startTime":"0","endTime":"0","summary":"Bybit Türkiye, a partner of the global cryptocurrency exchange Bybit, has been recognised as a crypto asset service provider by Turkey’s Capital Markets Board .This approval enables the platform to operate within Turkey's regulatory framework for the crypto industry.Operating through its local entity, Narkasa Yazilim Ticaret Anonim Sirketi, Bybit Türkiye has prioritised compliance with Turkish regulations since its rebranding in June 2024.Bybit Türkiye’s country manager, Kutluhan Akin, expressed satisfaction with the recognition, stating, \"We are pleased to be included in the CMB’s list of operating exchanges.\". The recognition allows Bybit Türkiye to continue offering its services to local users, including the integration of Turkish lira trading pairs and partnerships with banks like Ziraat Bank and Vakifbank.Bybit Türkiye emphasises providing reliable customer support with localised services available 24/7.As of September 23, the Turkish lira accounted for 0.07% of Bitcoin trading v","market":null,"thumbnail":"https://images.grafa.com/grafa/media-cryptocurrencies-bybit-t-rkiye-recognised-by-turkish-regulator-with-key-approval-277976-638627309413883062.webp","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-cryptocurrencies-bybit-t-rkiye-recognised-by-turkish-regulator-with-key-approval-277976-638627309413883062.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/cryptocurrencies-bybit-t-rkiye-recognised-by-turkish-regulator-with-key-approval-277976?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USDT.USD.CC","TON.USD.CC","RNDR.USD.HKCC","BK7067","BTC.USD.HKCC","APT.USD.HKCC","APT.USD.CC","USDT.USD.HKCC","CMB.AU","TON.USD.HKCC"],"gpt_icon":0}],"profile":{"websiteUrl":"","stockEarnings":[{"period":"1week","weight":0.0714},{"period":"1month","weight":-0.1429},{"period":"3month","weight":-0.2771},{"period":"6month","weight":-0.3333},{"period":"1year","weight":32.3333},{"period":"ytd","weight":-0.25}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0215},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.0787},{"period":"1year","weight":0.1756},{"period":"ytd","weight":0.0718}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.137653},{"month":2,"riseRate":0.416667,"avgChangeRate":0.058201},{"month":3,"riseRate":0.416667,"avgChangeRate":0.032538},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.089407},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.066504},{"month":6,"riseRate":0.545455,"avgChangeRate":7.289051},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.026494},{"month":8,"riseRate":0.545455,"avgChangeRate":0.039675},{"month":9,"riseRate":0.25,"avgChangeRate":-0.094477},{"month":10,"riseRate":0.5,"avgChangeRate":0.136283},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.047892},{"month":12,"riseRate":0.166667,"avgChangeRate":0.060192}],"exchange":"ASX","name":"Cambium Bio Limited","nameEN":"Cambium Bio Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cambium Bio Limited(CMB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cambium Bio Limited(CMB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cambium Bio Limited,CMB.AU,Cambium Bio Limited股票,Cambium Bio Limited股票老虎,Cambium Bio Limited股票老虎国际,Cambium Bio Limited行情,Cambium Bio Limited股票行情,Cambium Bio Limited股价,Cambium Bio Limited股市,Cambium Bio Limited股票价格,Cambium Bio Limited股票交易,Cambium Bio Limited股票购买,Cambium Bio Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cambium Bio Limited(CMB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cambium Bio Limited(CMB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}